PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC13231543::ACT047741

sP10

Evidence text

Paper-level observation

WB analysis revealed significant downregulation of TGFβ1, α-SMA, and phosphorylated Smad2 (p-Smad2) (Fig. 6A).
figureConfidence: medium

Assay observation

Activity
Metabolic/Cardiovascular
Subtype
Not reported by source
Measure
qualitative
Comparator
=
Raw observation
downregulated TGFβ1, α-SMA, and phosphorylated Smad2
Normalized measurement
=1
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
LX-2
Assay method
Not reported by source
Sequence
YGRKKRRQRRRCGPVWFLIFSYFLFFSISLARGPC
Standardization
ready simple

Source publication

Peptide aptamer sP10 targeting NPM1 attenuates liver fibrosis and hepatocellular carcinoma.

Journal of Translational Medicine · 2026

DOI 10.1186/s12967-026-08144-8 PMC13231543
Parent mention

Related peptide identities

PEPDIA-PLP-003251

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.